<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
        xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"
        xmlns:xhtml="http://www.w3.org/1999/xhtml">
  <url>
    <loc>https://global.investnews.co.kr/news/osong-lanzhou-bioindustry-cooperation</loc>
    <lastmod>2026-10-15T18:09:19+09:00</lastmod>
    <xhtml:link rel="alternate" hreflang="en" href="https://global.investnews.co.kr/news/osong-lanzhou-bioindustry-cooperation"/>
    <xhtml:link rel="alternate" hreflang="ja" href="https://global.investnews.co.kr/ja/news/osong-lanzhou-bioindustry-cooperation"/>
    <xhtml:link rel="alternate" hreflang="vi" href="https://global.investnews.co.kr/vi/news/osong-lanzhou-bioindustry-cooperation"/>
    <xhtml:link rel="alternate" hreflang="zh" href="https://global.investnews.co.kr/zh/news/osong-lanzhou-bioindustry-cooperation"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://global.investnews.co.kr/news/osong-lanzhou-bioindustry-cooperation"/>
    <news:news>
      <news:publication>
        <news:name>INVEST NEWS</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-15T18:09:19+09:00</news:publication_date>
      <news:title><![CDATA[Proposal Links Osong and Lanzhou to Support Korea-China Bioindustry Cooperation]]></news:title>
      <news:keywords><![CDATA[Osong, Lanzhou, Korea-China cooperation, bioindustry, market entry, regulatory support, joint clinical trials]]></news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://global.investnews.co.kr/storage/investnews-global/2026/10/4315cf16-d1f5-45be-ac3f-41c6dea5f03b-2540831a-og16x9.webp</image:loc>
      <image:caption><![CDATA[A proposal at a National Assembly of the Republic of Korea forum called for linking bioindustry hubs in Osong and Lanzhou to help companies with facilities, research support, regulatory information and local partners. Speakers also urged phased cooperation, starting with focused projects such as technology transfer, regulatory information exchange and joint clinical trials in rare diseases and pediatrics.]]></image:caption>
      <image:title><![CDATA[Proposal Links Osong and Lanzhou to Support Korea-China Bioindustry Cooperation]]></image:title>
    </image:image>
  </url>
  <url>
    <loc>https://global.investnews.co.kr/news/konex-market-report-september-2026</loc>
    <lastmod>2026-10-14T12:05:38+09:00</lastmod>
    <xhtml:link rel="alternate" hreflang="en" href="https://global.investnews.co.kr/news/konex-market-report-september-2026"/>
    <xhtml:link rel="alternate" hreflang="ja" href="https://global.investnews.co.kr/ja/news/konex-market-report-september-2026"/>
    <xhtml:link rel="alternate" hreflang="vi" href="https://global.investnews.co.kr/vi/news/konex-market-report-september-2026"/>
    <xhtml:link rel="alternate" hreflang="zh" href="https://global.investnews.co.kr/zh/news/konex-market-report-september-2026"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://global.investnews.co.kr/news/konex-market-report-september-2026"/>
    <news:news>
      <news:publication>
        <news:name>INVEST NEWS</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-14T12:05:38+09:00</news:publication_date>
      <news:title><![CDATA[[September 2026 KONEX Monthly Market Report] Trading Value Decreases by 39%... New Listings Follow as Transfer Listings Face Obstacles]]></news:title>
      <news:keywords><![CDATA[KONEX, Korea Exchange, Bon Systems, SK Signet, Ensol Bioscience, PharmaResearch Bio, Jincostech]]></news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://global.investnews.co.kr/storage/investnews-global/2026/10/00ddafa8-5bd1-4bfb-b5f4-17faf791c4f4-8765fbb7-og16x9.webp</image:loc>
      <image:caption><![CDATA[In September, the KONEX market showed mixed results with an increase in trading volume but a 39.4% decrease in trading value. While the first case of transfer listing to KONEX for companies facing delisting was delayed due to court decisions, new listing applications continue.]]></image:caption>
      <image:title><![CDATA[[September 2026 KONEX Monthly Market Report] Trading Value Decreases by 39%... New Listings Follow as Transfer Listings Face Obstacles]]></image:title>
    </image:image>
  </url>
  <url>
    <loc>https://global.investnews.co.kr/news/s-innovations-amr-pre-a-investment</loc>
    <lastmod>2026-10-14T11:02:01+09:00</lastmod>
    <xhtml:link rel="alternate" hreflang="en" href="https://global.investnews.co.kr/news/s-innovations-amr-pre-a-investment"/>
    <xhtml:link rel="alternate" hreflang="ja" href="https://global.investnews.co.kr/ja/news/s-innovations-amr-pre-a-investment"/>
    <xhtml:link rel="alternate" hreflang="vi" href="https://global.investnews.co.kr/vi/news/s-innovations-amr-pre-a-investment"/>
    <xhtml:link rel="alternate" hreflang="zh" href="https://global.investnews.co.kr/zh/news/s-innovations-amr-pre-a-investment"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://global.investnews.co.kr/news/s-innovations-amr-pre-a-investment"/>
    <news:news>
      <news:publication>
        <news:name>INVEST NEWS</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-14T11:02:01+09:00</news:publication_date>
      <news:title><![CDATA[[Series] S Innovations, an AMR operation automation company, attracts 3 billion won in Pre-A investment to advance technology]]></news:title>
      <news:keywords><![CDATA[S Innovations, AMR, SynK, Quantum Ventures Korea, Korea Credit Guarantee Fund, Daekyo Investment, autonomous mobile robot]]></news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://global.investnews.co.kr/storage/investnews-global/2026/10/5731c1d0-0893-4fa7-83f5-086a1e6f5457-54ca211e-og16x9.webp</image:loc>
      <image:caption><![CDATA[S Innovations, an autonomous mobile robot (AMR) operation automation platform company, has secured 3 billion won in Pre-A funding. The investment, which includes participation from Quantum Ventures Korea, Korea Credit Guarantee Fund, and Daekyo Investment, brings the company's cumulative investment to 4.4 billion won.]]></image:caption>
      <image:title><![CDATA[[Series] S Innovations, an AMR operation automation company, attracts 3 billion won in Pre-A investment to advance technology]]></image:title>
    </image:image>
  </url>
  <url>
    <loc>https://global.investnews.co.kr/news/ms-bio-ipo-kosdaq-subscription-success</loc>
    <lastmod>2026-10-13T19:12:07+09:00</lastmod>
    <xhtml:link rel="alternate" hreflang="en" href="https://global.investnews.co.kr/news/ms-bio-ipo-kosdaq-subscription-success"/>
    <xhtml:link rel="alternate" hreflang="ja" href="https://global.investnews.co.kr/ja/news/ms-bio-ipo-kosdaq-subscription-success"/>
    <xhtml:link rel="alternate" hreflang="vi" href="https://global.investnews.co.kr/vi/news/ms-bio-ipo-kosdaq-subscription-success"/>
    <xhtml:link rel="alternate" hreflang="zh" href="https://global.investnews.co.kr/zh/news/ms-bio-ipo-kosdaq-subscription-success"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://global.investnews.co.kr/news/ms-bio-ipo-kosdaq-subscription-success"/>
    <news:news>
      <news:publication>
        <news:name>INVEST NEWS</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-13T19:12:07+09:00</news:publication_date>
      <news:title><![CDATA[[IPO] MS Bio's competitiveness as a 'profitable bio company' pays off... Subscription ratio of 1538:1]]></news:title>
      <news:keywords><![CDATA[MS Bio, KOSDAQ Market, IPO, KB Securities, medical devices, human tissue]]></news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://global.investnews.co.kr/storage/investnews-global/2026/10/e181cd7a-d36e-4d86-bbf1-7a8148cf6230-47fe42ed-og16x9.webp</image:loc>
      <image:caption><![CDATA[MS Bio successfully completed its public subscription for its upcoming KOSDAQ listing on the 22nd, driven by expectations for the medical device market and the company's profitability.]]></image:caption>
      <image:title><![CDATA[[IPO] MS Bio's competitiveness as a 'profitable bio company' pays off... Subscription ratio of 1538:1]]></image:title>
    </image:image>
  </url>
</urlset>
